Igg2aκ isotype control

Samples were obtained from blood, spleen, or tumors, as indicated. Tumor samples were weighed after harvest and digested/dissociated, and total cells were counted. Excess surface marker antibodies were mixed with cells and incubated at 4°C for 30 min. After treatment with the Cyto-Fast™ Fix/Perm Buffer Set (Biolegend 426803) or Foxp3/Transcription Factor Staining Buffer Set (Invitrogen 00-5523-00), intracellular markers or Nucleoprotein were stained with the corresponding antibodies. The panel included the following reagents: Zombie NIR™ Fixable Viability Kit, anti-CD45 (Biolegend 103128), anti-CD3 (Biolegend 100203) anti-CD4 (Biolegend 100539), anti-CD8a (Biolegend 100711), anti-CD100 (BD 745346), IgG2a,κ Isotype Control (BD 563236), anti-CD11B (Biolegend 101255), anti-F4/80 (Biolegend 123135), anti-CD11C (Biolegend 117317), anti-CD86 (Biolegend 105037), and anti-CD206 (Biolegend 141706), anti-PD-1 (Biolegend 135227), anti-LAG-3 (Biolegend 125209), anti-TIM-3 (Biolegend 119717), anti-TIGIT (Biolegend 142111).